Christina M. Davis serves as a Lecturer in the Department of Chemistry at Valparaiso University, where she contributes to both teaching and research in organic and supramolecular chemistry disciplines. Educational background: Ph.D. in Organic Chemistry – University of Texas (2014) B.S. – College of William and Mary (2010) Her research program centers on supramolecular recognition systems and photoresponsive materials , with particular focus on tetrathiafulvalene-calix[4]pyrrole architectures. Current investigations examine ion-regulated binding of fullerenes, photoinduced electron transfer in porphyrin-containing ensembles, and fluorescence modulation in photochromic nanoparticle systems. This work bridges synthetic organic chemistry with photophysical characterization to develop stimuli-responsive molecular devices. Publication analysis reveals consistent output in high-impact chemistry journals between 2011-2014, demonstrating expertise at the intersection of organic synthesis, nanomaterials, and photophysics. Her research shows particular strength in designing supramolecular systems with tunable electronic properties for potential sensing applications. Scientific Awards: No specific awards documented in available materials Advising and Resources: Active research program evidenced by recent publications Collaborative work with multiple co-investigators Membership in American Chemical Society No explicit information on current students or grant funding Research activities appear integrated within the Department of Chemistry infrastructure without indication of a separately named laboratory facility.
Andrew Pickering, Ph.D., is an Associate Professor in the Department of Integrative Biology and Pharmacology at McGovern Medical School, UTHealth Houston. He directs the Geroscience Core at the Institute on Aging, overseeing initiatives like the Annual Symposium on Aging Research and the Harry E. Bovay, Jr. Foundation Pilot Grants Program, which funds junior faculty in aging research. His research centers on proteostasis in aging and neurodegeneration. Key areas include: Proteasome dysfunction in Alzheimer's disease and development of proteasome-activating therapeutics Mitochondrial thioredoxin systems as metabolic regulators and lifespan extenders Protein translation dynamics, where early-life repression extends lifespan via juvenile hormone pathways Cross-species mechanisms of aging using Drosophila, mice, and comparative biology His recent publications (2019-2024) focus on proteasome augmentation therapies for Alzheimer's, translational regulation of aging, mitochondrial metabolism, and microbiome impacts on neurodegeneration. These reflect a consistent theme: targeting proteostatic mechanisms to combat age-related functional decline. Dr. Pickering leads the Pickering Aging Lab, investigating aging drivers through biochemical, genetic, and pharmacological approaches. The lab collaborates with clinical researchers to translate findings into therapeutic strategies for age-related diseases.
Björn Kull serves as Head of Department for Joint Operational Support within the Department for Research Support and External Relations at Karolinska Institutet, one of Europe's foremost medical universities. He earned his Doctoral Degree of Medicine from Karolinska Institutet's Department of Physiology and Pharmacology in 2000, establishing a strong foundation for his career in academic research and administration. Professor Kull's research expertise spans pharmaceutical sciences, pharmacology, toxicology, and neurosciences, with a particular focus on adenosine receptor pharmacology and its interactions with dopamine signaling pathways. His work has significantly contributed to understanding receptor signaling mechanisms in the central nervous system. Analysis of his publication record from 1996-2012 reveals a consistent focus on adenosine receptors, particularly the A2A subtype, and their interactions with dopamine receptors. His research trajectory shows progression from basic receptor characterization to more complex studies of receptor interactions and signaling pathways, demonstrating increasing sophistication in experimental approaches over time. While no specific scientific awards are mentioned in the available information, Professor Kull's publication record in high-impact journals such as Nature Biotechnology, Molecular Pharmacology, and Neuroscience indicates recognition within his field. His transition from active research to research administration reflects a career evolution common among senior academics who apply their scientific expertise to institutional leadership. In his current administrative role, Professor Kull oversees research support operations at Karolinska Institutet, leveraging his deep understanding of the research process to facilitate scientific discovery across the institution. His leadership contributes to maintaining Karolinska Institutet's position at the forefront of medical research.
Roger Estrada Weaver is a Full Professor at the IQS School of Engineering, Universitat Ramon Llull, where he works in the Department of Organic and Pharmaceutical Chemistry as part of the Pharmaceutical Chemistry Group. He maintains an active research profile with an h-index of 749 and has been involved in numerous research projects since 2007. His research focuses on RNA Biochemistry, Heterocyclic Compound Chemistry, Drug Discovery, Small Molecule Biochemistry, and targeted cancer therapies. He has made significant contributions to the development of CXCR4 inhibitors, IRAK4 degraders, and compounds targeting pathogenic RNA structures, with particular emphasis on treatments for lymphoma and other hematological malignancies. His recent publications demonstrate a strong trend toward computational and molecular approaches to drug design, particularly for cancer therapeutics. His work integrates molecular modeling with synthetic chemistry to develop novel compounds targeting specific pathways in malignancies, with increasing focus on precision medicine approaches for hematological cancers. Professor Weaver leads the GQF: Grup de Química Farmacèutica research group and is Principal Investigator for several significant projects including DisX4lymph (focused on CXCR4 allosteric inhibitors and IRAK4 degraders for B-cell lymphoma treatment) and PROTEOblood (a Franco-Spanish cooperative network for proteinopathy analysis and development of individualized therapies in hematological cancers). His research has been funded by the Agencia Estatal de Investigación, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), European Commission, and Universitat Ramon Llull. His laboratory work centers around the Pharmaceutical Chemistry Group at IQS, where his team develops innovative approaches to target RNA structures and protein interactions in cancer. Current research directions include covalent reversible inhibitors of IRAK4, non-symmetrical CXCR4 inhibitors, structural simplification methods for hit discovery, and photochemical synthesis techniques for heterocyclic compounds with therapeutic potential.
Jonas Sigurd Mortensen serves as an Assistant Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen, specifically within the Molecular and Cellular Pharmacology division. His research program bridges fundamental biochemistry with pharmacological applications, focusing on two interconnected domains: the development of novel detergents for membrane protein stabilization and investigations into neurotransmitter systems, particularly GABA transporters and kinase signaling pathways. Dr. Mortensen's research interests center around membrane protein biochemistry and neuropharmacology. His work in detergent development addresses a critical technical challenge in structural biology—maintaining the stability and functionality of membrane proteins outside their native lipid environment. He has systematically investigated how structural variations in detergents (including rigidity-flexibility balance, core flexibility, and pendant chain characteristics) affect protein stability. This foundational work enables more effective structural and functional studies of membrane proteins, which represent important drug targets. Concurrently, his pharmacological research explores GABA transporter modulation as a therapeutic strategy for neurological disorders and examines allosteric factors in kinase regulation related to GHB pharmacology, demonstrating the translational potential of his biochemical expertise. Analysis of Dr. Mortensen's publication record reveals a strong trajectory in membrane protein biochemistry, with numerous papers describing innovative amphiphile designs including various maltosides, tetraglucosides, and other specialized detergents. His recent work has expanded into neuropharmacology, with publications examining GABA transporter modulation for neurological disease treatment and investigating calcium/calmodulin-responsive kinase II domains. This evolution demonstrates how his technical expertise in membrane protein stabilization directly supports investigations of pharmacologically relevant targets. Dr. Mortensen maintains extensive collaborations with researchers across multiple institutions, as evidenced by his co-authorship on numerous publications with scientists including Claus J. Loland, Paul R. Eriksson, and various international collaborators. His research output includes 35 publications comprising 33 journal articles, 1 book chapter, and 1 review article, with significant citations and engagement on academic platforms like Mendeley and social media. His laboratory likely employs a comprehensive suite of biochemical, biophysical, and pharmacological techniques to investigate membrane protein structure-function relationships and develop novel pharmacological tools. While specific grant information isn't detailed in the available text, his productive publication record across high-impact journals suggests successful funding of his research program. Dr. Mortensen's work has practical implications for drug discovery, particularly in neurological disorders where membrane proteins serve as important therapeutic targets, positioning his research at the critical intersection of basic science and therapeutic development.
Gertrud Malene Hjortø is an Associate Professor at the University of Copenhagen's Faculty of Health and Medical Sciences, Department of Biomedical Sciences, specializing in Molecular and Translational Pharmacology. Her research focuses on chemokine receptors, particularly CCR7, and their role in immune cell recruitment and positioning in the body. Dr. Hjortø leads a research group of four people and teaches approximately 550 hours per year across various medical and dental programs at the university. Dr. Hjortø earned her PhD from the Department of Molecular Biology and Virology at the University of Copenhagen and Novo Nordisk in 2002. Her educational background includes a Master's degree from Novo Nordisk A/S and the Department of Molecular Biology at KU (1996-97), and undergraduate studies in Biology (1992-97) and Biochemistry (1991-92) at the University of Copenhagen. Dr. Hjortø's research centers on understanding the molecular mechanisms of chemokine receptors, with special emphasis on CCR7 and its ligands CCL19, CCL21, and CCL21Tailless. Her work investigates how these receptors control immune responses through dendritic cell and T cell recruitment to lymph nodes. A key discovery from her lab is that post-translational modifications of chemokine receptors can be targeted with externally added peptides to enhance ligand-receptor interactions. This led to a patent application for "Chemotaxis potentiating peptides and uses thereof," which aims to improve immune responses, particularly in cancer immunotherapy. Her research employs classical pharmacological methods, time-lapse microscopy for tracking immune cell migration, and analysis of receptor-mediated signaling events. The publication record of Dr. Hjortø demonstrates a strong focus on chemokine receptor pharmacology, with recent work expanding into related receptors like GPR183 and broader applications in cancer immunotherapy and inflammatory diseases. Her most recent publications (2022-2024) explore structural determinants of receptor-ligand interactions, biased signaling, and the role of glycosaminoglycans in chemokine presentation. Many of her papers involve international collaborations, particularly with researchers in the United States, reflecting the global nature of immunological research. Patent: "Chemotaxis potentiating peptides and uses thereof" Research funding from Innovation Foundation Denmark (2021, 1.385.000 DKK) Novo Nordisk BII grant (2020, 952.000 DKK) Carlsberg Foundation grants (2018, 600.000 DKK; 2013, 380.000 DKK) PoC KU grant (2018, 225.000 DKK) Gangsted Foundation grant (2015, 340.000 DKK) AP Møller Foundation grant (2014, 46.000 DKK) Dr. Hjortø actively supervises multiple graduate students across various projects related to chemokine receptor pharmacology and immune cell migration. Her supervision spans PhD, M.Sc., and B.Sc. levels, with current projects including "Immune boosting peptides for improved immune cell activation" and "Microshaping hydrogels and their chemistry in 3D for optimizing/validating DC migration." She has secured significant research funding from multiple Danish foundations and international organizations, supporting her work on chemokine receptor modulation and its therapeutic applications. Dr. Hjortø collaborates with leading researchers worldwide, including Brian F. Volkman and Christopher T. Veldkamp from Wisconsin (US), Benjamin A.H. Jensen from the University of Copenhagen, and cancer immunotherapy experts Inge Marie Svane and Pawel Kalinski. Dr. Hjortø leads the Hjortø group, which investigates how CCR7 and its ligands orchestrate immune responses through controlled recruitment of dendritic cells and T cells to lymph nodes. Current work explores the potential of C21-TP (a naturally occurring peptide) to improve dendritic cell-based anti-cancer vaccines. The group employs advanced techniques including time-lapse microscopy for tracking immune cell migration, pharmacological analysis of receptor signaling, and structural studies of receptor-ligand interactions.
Søren Gøgsig Faarup Rasmussen serves as an Associate Professor in the Department of Neuroscience within the Faculty of Health and Medical Sciences at the University of Copenhagen. His research is conducted through the Neuropharm and Genetics research group, with laboratory facilities located at Blegdamsvej 3B in Copenhagen. Dr. Rasmussen's research focuses on molecular neuropharmacology, particularly the structural and functional characterization of G protein-coupled receptors (GPCRs) and neurotransmitter transporters. His laboratory employs advanced techniques including single-molecule imaging, structural biology approaches, and biophysical analyses to investigate conformational dynamics of receptors at unprecedented resolution. His work bridges fundamental molecular mechanisms with implications for neurological disorders and drug development. Analysis of his publication record reveals a consistent trajectory of high-impact research on membrane protein dynamics, with publications spanning top-tier journals including Cell, Nature Communications, and Science Advances. His work demonstrates strong interdisciplinary collaboration across biochemistry, biophysics, and pharmacology, with notable contributions to understanding receptor activation mechanisms and transporter function. Dr. Rasmussen leads an active research laboratory (Rasmussen Lab) that maintains a strong publication output, with 54 documented research contributions. His work has attracted significant scientific attention, with several publications receiving substantial citations and media coverage, including news features and social media discussion across multiple platforms.
Gáspár Pándy-Szekeres serves as an Academic Employee at the University of Copenhagen's Faculty of Health and Medical Sciences within the Department of Drug Design and Pharmacology. His research focuses on computational approaches to G protein-coupled receptors (GPCRs) and related signaling proteins, with significant contributions to bioinformatics resource development. His primary research interests include GPCR bioinformatics, molecular dynamics simulation of receptor systems, computational drug design methodologies, and specialized database construction for biological targets. He employs advanced computational techniques to analyze receptor structure-function relationships, ligand binding mechanisms, and allosteric modulation sites critical for pharmaceutical development. Recent publications demonstrate a clear trajectory toward integrating artificial intelligence (AlphaFold2) with experimental data to model physiological ligand complexes and receptor dynamics. His work emphasizes large-scale analysis of molecular dynamics trajectories to identify cryptic binding pockets and lateral access pathways in GPCRs, advancing targeted drug discovery. As a core contributor to the GPCRdb platform, he leads international collaborations focused on expanding receptor classification systems, developing structure-similarity search tools, and incorporating odorant receptor data. His research group maintains active partnerships across European institutions for advancing computational pharmacology frameworks.
Mette Homann Poulsen serves as an Assistant Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen, with additional affiliation as a Guest Researcher in the Biopharmaceuticals section of the same department. Her research bridges molecular pharmacology and drug design with a focus on ion channel mechanisms. Her primary research interests span Ion Channel Pharmacology , Receptor Biology , and Molecular Pharmacology , particularly investigating P2X and AMPA receptor families. Her work examines pH-sensing mechanisms, transporter-channel crosstalk, and receptor variants in disease contexts including cancer and mental disorders. She employs techniques ranging from protein engineering to cellular electrophysiology to develop pharmacological tools and understand disease mechanisms. Analysis of her recent publications (2018-2025) reveals a strong emphasis on receptor variant functionality, with significant contributions to understanding P2X7 receptor polymorphisms in pancreatic cancer and mental health disorders. Her work integrates biophysical approaches with disease modeling, demonstrating translational potential in oncology and neuroscience. No scientific awards were explicitly mentioned in the source material. Dr. Poulsen maintains active collaborations with researchers including S.A. Pless, N.R. Jørgensen, and I. Novak across multiple institutions. Her research has attracted substantial attention, with publications generating significant Mendeley readership and social media engagement, particularly her 2020 Nature Communications paper which garnered 117 Mendeley readers and 17 social media interactions. While specific laboratory or team structures weren't detailed in the source material, her publication patterns suggest active participation in interdisciplinary research groups focusing on receptor pharmacology and protein engineering within the Department of Drug Design and Pharmacology.
Patrick Griffin is a Professor and Scientific Director at The Scripps Research Institute (TSRI) Scripps Florida, where he serves in the Department of Molecular Therapeutics. With over 25 years of experience in drug discovery and development, Dr. Griffin has established himself as a leading researcher in protein structure and nuclear receptor signaling. His career spans both industry and academia, with significant contributions to pharmaceutical development including key work on Januvia (a DPP4 inhibitor now in clinical use). Ph.D. in Chemistry from the University of Virginia under Professor Donald F. Hunt Postdoctoral Fellowship with Professor Leroy Hood at Caltech Former Chief Science Officer at ExSAR Corporation Former Senior Director of Chemistry at Merck Research Laboratories Dr. Griffin's research program focuses on understanding nuclear receptor (NR) signaling using structural, chemical and biological approaches. His laboratory has made significant contributions to understanding the mechanism of ligand activation of NRs such as PPARs, RORs, REV-ERBs, LRH1, VDR, ER, GR, and PR. Through the use of mutagenesis, HDX-MS, crystallography, proteomics and genomics, his team studies the structure-function relationships of nuclear receptors, enzymes, and G protein coupled receptors (GPCRs). A major emphasis of his chemical biology program is developing functionally selective and promoter-specific modulators targeting diseases such as cancer, autoimmune disorders, obesity, and diabetes. Dr. Griffin's lab is particularly well-known for developing and applying biophysical methods including HDX and XL-MS platforms for analyzing protein plasticity, with a focus on nuclear receptors, enzymes, and GPCRs. Dr. Griffin's recent publications (2022-2025) demonstrate continued innovation in structural proteomics, nuclear receptor biology, and therapeutic development. His work shows a clear trajectory from fundamental protein structure research toward translational applications, particularly in metabolic disorders, cancer, and neurological conditions. A significant theme across his recent work is the development of non-muscle myosin II inhibitors with therapeutic potential, reflecting his long-standing interest in protein structure-function relationships and their therapeutic modulation. His research continues to bridge structural biology, chemical biology, and drug discovery, with particular emphasis on nuclear receptor signaling pathways and their role in metabolic regulation. Dr. Griffin's research impact is evidenced by his publication record of over 240 peer-reviewed manuscripts, an h-index of 83 (58 since 2016), and an i10-index of 223 according to Google Scholar. Dr. Griffin has served as PI, Co-PI, and co-investigator on numerous NIH-funded grants. Notable funding includes leadership of "The Comprehensive Center for Chemical Probe Discovery and Optimization at Scripps," a 6-year U54 MLPCN Roadmap initiative. He co-founded Ember, a biotech company funded by Third Rock Ventures, based on work from a RC4 collaboration with Bruce Spiegelman at Dana Faber. Dr. Griffin has maintained a 13-year collaboration with Eli Lilly and serves as PI on grants with private biotechs including Synkine Therapeutics. As Co-PI on a NIH Blueprint UH3 grant, he co-founded Myosin Therapeutics, whose clinical candidate emerged from this NIH-funded program. Dr. Griffin leads a research program that integrates structural biology, chemical biology, and drug discovery approaches. His laboratory has developed advanced HDX-MS and XL-MS platforms for protein structure analysis. The team's work spans from fundamental protein structure studies to translational drug discovery, with particular expertise in nuclear receptor biology. His lab has made significant contributions to understanding nuclear receptor signaling mechanisms and developing novel therapeutic approaches targeting these pathways.
Patrick Griffin is Professor and former Chair of the Department of Molecular Therapeutics at The Scripps Research Institute, with over 25 years of experience in protein structure research and drug discovery. His career spans both industry and academia, with significant contributions to structural proteomics and nuclear receptor pharmacology. Dr. Griffin earned his Ph.D. in Chemistry from the University of Virginia under Professor Donald F. Hunt, where he contributed to groundbreaking work in protein sequencing using tandem mass spectrometry. He completed postdoctoral training with Professor Leroy Hood at Caltech before holding leadership positions at Merck Research Laboratories and ExSAR Corporation. His research program focuses on protein structure-function relationships, particularly mutational- and ligand-mediated alterations in protein structural plasticity. Using mutagenesis, HDX-MS, crystallography, proteomics and genomics, his laboratory investigates nuclear receptors (PPARs, RORs, REV-ERBs, LRH1, VDR), enzymes, and GPCRs. The lab has made significant contributions to understanding ligand activation mechanisms and developing functionally selective modulators for diseases including cancer, autoimmune disorders, obesity, and diabetes. Analysis of Dr. Griffin's recent publications reveals a strong emphasis on nuclear receptor structural biology, particularly PPAR family members, with increasing integration of structural proteomics techniques to study therapeutic targets. His work shows a clear trajectory from basic structural understanding to therapeutic applications, with multiple discoveries translated into clinical candidates. Dr. Griffin serves as PI or Co-PI on multiple NIH-funded projects including a U54 MLPCN Roadmap initiative, RC4 programs, and U19 NCDDDG grants. He maintains a 13-year collaboration with Eli Lilly and has co-founded biotech companies including Ember and Myosin Therapeutics based on his research findings. His laboratory has developed advanced biophysical methods, particularly in HDX and XL-MS platforms for analyzing protein plasticity. The research group operates at the intersection of structural biology, chemical biology, and translational medicine, with strong industry partnerships facilitating the translation of basic discoveries into therapeutic candidates.
